Evidence map›Paper›PMID 41152620›Full record

Trial reportGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026

POYANG: A phase III randomized clinical trial of faricimab for choroidal neovascularization secondary to pathologic myopia: study design and rationale.

Timothy Y Y Lai, Luis Arias, Chui Ming Gemmy Cheung, Aude Couturier, Wenxin Liu, Olivia E O'Leary, Neala Rafijah, Neil Shah, Young Hee Yoon, Shriji Patel and 1 more

Abstract readMulticenter StudyRandomized Controlled TrialClinical Trial, Phase III
PubMed Publisher
In one paragraph

Trial report in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Timothy Y Y LaiDepartment of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong.
Luis AriasHead of Retina Department, Department of Ophthalmology, Hospital Universitari de Bellvitge, Barcelona, Spain.
Chui Ming Gemmy CheungSingapore Eye Research Institute, Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.
Aude CouturierOphthalmology Department, Université Paris Cité, AP-HP, Hôpital Lariboisière, F-75010, Paris, France.
Wenxin LiuF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Olivia E O'LearyF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Neala RafijahGenentech, Inc, South San Francisco, CA, USA.
Neil ShahMoorfields Eye Hospital NHS Foundation Trust, London, UK.
Young Hee YoonDepartment of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Shriji PatelGenentech, Inc, South San Francisco, CA, USA. pates122@gene.com.
POYANG Study investigators

Funding

F. Hoffmann-La Roche F. Hoffmann-La Roche
6 · The paper itself

Abstract

purposeTo describe the study design of the POYANG study, an international, randomized, double-masked, multicenter, active comparator-controlled Phase 3 trial assessing the efficacy and safety of faricimab, a dual inhibitor of angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A), in patients with choroidal neovascularization secondary to pathologic myopia (mCNV).

methodsAdult patients with treatment-naïve mCNV will be randomized 1:1 to receive either faricimab 6.0 mg or ranibizumab 0.5 mg. After an initial active intravitreal treatment administration at randomization (Day 1), subsequent treatment will be administered using a pro-re-nata (PRN) dosing regimen. Patients will be seen monthly over a 48-week study period and active study drug will be administered when protocol-defined retreatment criteria are met. Criteria are based on changes in best-corrected visual acuity (BCVA), central subfield thickness (CST) or examination findings consistent with mCNV activity. A sham procedure will be administered to patients at study visits when there is no active mCNV disease activity, in order to maintain masking.

resultsThis study aims to recruit approximately 280 patients with mCNV from 11 countries in the Asia-Pacific and European regions. The primary endpoint is non-inferiority of faricimab versus ranibizumab in change from baseline in BCVA averaged over Weeks 4, 8 and 12. Secondary endpoints include change in CST over time and number of treatments required. Incidence and severity of ocular and non-ocular adverse events will be assessed.

conclusionsPOYANG is a Phase 3 registrational trial investigating the efficacy and safety of faricimab in patients with choroidal neovascularization secondary to pathologic myopia.

Indexed as

Choroidal NeovascularizationMyopia, DegenerativeAdultAngiogenesis InhibitorsAngiopoietin-2Antibodies, BispecificDose-Response Relationship, DrugDouble-Blind MethodFemaleFluorescein AngiographyFollow-Up StudiesHumansIntravitreal InjectionsMaleMiddle AgedRanibizumabAngiogenesis InhibitorsAngiopoietin-2Antibodies, BispecificfaricimabRanibizumabVascular Endothelial Growth Factor A(3–5): pathologic myopia; choroidal neovascularizationAng-2Anti-VEGF

Identifiers

PMID41152620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.